Home > Market > Market Stats >  Biocon

Biocon

Sector: Biotechnology & Drugs
Powered by
290.95 +4.05 (1.41%)
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y

Price Range

Today’s Low 285.05
Today’s High 292.4
52 Week Low 273.65
52 Week High 410.5

Key Metrics

  • Market Cap (In Cr) 34186.94
  • Beta 0.57
  • Div. Yield (%) 0.17
  • P/B 4.08
  • TTM P/E 51.88
  • Peg Ratio 1.26
  • Sector P/E 25.8
  • D/E -
  • Open Price 285.05
  • Prev Close 286.9
View All Metrics on Mint Genie

Analysis

Price Analysis
  • 1 Week
    -0.92%
  • 3 Months
    -6.99%
  • 6 Month
    -14.53%
  • YTD
    -21.34%
  • 1 Year
    -20.89%
Risk Meter
  • 30% Low risk
  • 30% Moderate risk
  • 30% Balanced Risk
  • 30% High risk
  • 30% Extreme risk
Recos
22 Analysts
  • Strong Sell
  • Sell
  • Hold
  • Buy
  • Strong Buy
Analysts' Views
  • Ratings
  • Current
  • Strong Sell
  • 1
  • Sell
  • 3
  • Hold
  • 4
  • Buy
  • 6
  • Strong Buy
  • 8

Financials

  • INCOME
  • BALANCE SHEET
  • Cashflow
  • Period
  • 2022
  • Total Revenue
  • 8184
  • Selling/ General/ Admin Expenses Total
  • 2920.9
  • Depreciation/ Amortization
  • 814.2
  • Other Operating Expenses Total
  • -445.1
  • Total Operating Expense
  • 7079.5
  • Operating Income
  • 1104.5
  • Net Income Before Taxes
  • 983.1
  • Net Income
  • 648.4
  • Diluted Normalized EPS
  • 5.97
  • Period
  • 2021
  • Total Revenue
  • 7143.1
  • Selling/ General/ Admin Expenses Total
  • 2762.8
  • Depreciation/ Amortization
  • 715.1
  • Other Operating Expenses Total
  • -326.6
  • Total Operating Expense
  • 6025.8
  • Operating Income
  • 1117.3
  • Net Income Before Taxes
  • 1067.7
  • Net Income
  • 740.5
  • Diluted Normalized EPS
  • 5.1
  • Period
  • 2020
  • Total Revenue
  • 6300.5
  • Selling/ General/ Admin Expenses Total
  • 2352.4
  • Depreciation/ Amortization
  • 552.2
  • Other Operating Expenses Total
  • -326.4
  • Total Operating Expense
  • 5180.8
  • Operating Income
  • 1119.7
  • Net Income Before Taxes
  • 1214.9
  • Net Income
  • 748.2
  • Diluted Normalized EPS
  • 6.13
  • Period
  • 2019
  • Total Revenue
  • 5514.4
  • Selling/ General/ Admin Expenses Total
  • 1988.6
  • Depreciation/ Amortization
  • 447.8
  • Other Operating Expenses Total
  • -251.9
  • Total Operating Expense
  • 4568.5
  • Operating Income
  • 945.9
  • Net Income Before Taxes
  • 1214.9
  • Net Income
  • 905.3
  • Diluted Normalized EPS
  • 7.7
  • Period
  • 2018
  • Total Revenue
  • 4129.7
  • Selling/ General/ Admin Expenses Total
  • 1499.9
  • Depreciation/ Amortization
  • 385
  • Other Operating Expenses Total
  • -146.5
  • Total Operating Expense
  • 3685.7
  • Operating Income
  • 444
  • Net Income Before Taxes
  • 610
  • Net Income
  • 372.4
  • Diluted Normalized EPS
  • 3.14
  • Period
  • 2017
  • Total Revenue
  • 3921.6
  • Selling/ General/ Admin Expenses Total
  • 1173.1
  • Depreciation/ Amortization
  • 277.2
  • Other Operating Expenses Total
  • -91.4
  • Total Operating Expense
  • 3217
  • Operating Income
  • 704.6
  • Net Income Before Taxes
  • 849.7
  • Net Income
  • 612.1
  • Diluted Normalized EPS
  • 5.16
View detailed financials on Mint Genie

Forecast

Income Sheet (In Cr) Net Income Vs Revenue
Returns Metrics (In Cr) ROA Vs ROE

Technical

Moving Average SMA
  • 5 Day282.24
  • 10 Day286.96
  • 20 Day293.31
  • 50 Day305.42
  • 100 Day315.38
  • 300 Day339.44

Peers

  • Price
  • Ratio
  • Name
  • Latest Price
  • Change
  • % Change
  • 52W High
  • 52W Low
  • Mkt. Cap
  • Biocon
  • 290.95
  • 4.05
  • 1.41
  • 410.5
  • 273.65
  • 34186.94
  • Lupin
  • 679.6
  • 25.6
  • 3.91
  • 979.25
  • 583.05
  • 29772.09

Corporate Actions

  • Board Meeting
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
  • Meeting Date
  • Purpose
  • 27-Jul-22
  • Quarterly Results
  • 28-Apr-22
  • Audited Results & Dividend
  • 20-Jan-22
  • Quarterly Results
  • 21-Oct-21
  • Quarterly Results
  • 22-Jul-21
  • Quarterly Results
  • 28-Apr-21
  • Audited Results & Final Dividend
  • 21-Jan-21
  • Quarterly Results

Company Profile

ABOUT Biocon

  • Industry Biotechnology & Drugs
  • ISIN INE376G01013
  • BSE Code 532523
  • NSE Code BIOCON

Biocon Limited is an India-based biopharmaceutical company that focuses to treat diabetes, cancer and autoimmune diseases. The Company is also focused on developing novel therapies for diabetes, oncology and immunology. The Company’s businesses segment includes Generics, Biosimilars, Novel Biologics and Research Services. The Company’s Generic Formulations and active pharmaceutical ingredients (API)products include Rosuvastatin, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company’s portfolio includes ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.

MANAGEMENT

  • Kiran Mazumdarshaw Executive Chairperson of the Board
  • Siddharth Mittal Chief Executive Officer, Managing Director, Executive Director
  • Indranil Sen Chief Financial Officer
  • Shreehas Tambe Deputy Chief Executive Officer
  • Amitava Saha Chief Human Resource Officer
  • Mayank Verma Compliance Officer, Company Secretary
  • Sriram A.V. Head - Quality
  • Seema Ahuja Chief Communications Officer
  • Prasad Deshpand Head - Supply Chain and Central Engineering
  • Vijaya Kumar Head - Operations

Company Summary

BIOCON SUMMARY

Biocon is trading 1.41% upper at Rs 290.95 as compared to its last closing price. Biocon has been trading in the price range of 292.4 & 285.05. Biocon has given -21.34% in this year & -0.92% in the last 5 days.

 

Biocon has TTM P/E ratio 51.88 as compared to the sector P/E of 25.8. There are 22 analysts who have initiated coverage on Biocon. There are 8 analysts who have given it a strong buy rating & 6 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.

 

The company posted a net profit of 144.4 Crores in its last quarter.

 

Listed peers of Biocon include Zydus Lifesciences (0.82%), Gland Pharma (0.26%), Biocon (1.41%) etc.

FAQs about Biocon

Biocon is trading at 290.95 as on 30 Sep, 2022 3:29:50 PM. This is 1.41% upper as compared to its previous closing price of 286.9
The market capitalization of Biocon is 34186.94 Cr as on 30 Sep, 2022 3:29:50 PM.
The average broker rating on Biocon is Buy. The breakup of analyst rating is given below -
  • 1 analysts have given a strong sell rating
  • 3 analysts have given a sell rating
  • 4 analysts have given a hold rating
  • 6 analysts have given a buy rating
  • 8 analysts have given a strong buy rating
The 52 wk high for Biocon is 410.5 whereas the 52 wk low is 273.65
Biocon can be analyzed on the following key metrics -
  • TTM P/E: 51.88
  • Sector P/E: 25.8
  • Dividend Yield: 0.17%
  • D/E ratio: -
Biocon reported a net profit of 648.4 Cr in 2022.

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout